ArticleBritish journal of haematology2014
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Article in British journal of haematology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.
- Unveiling the Prognostic Significance of BCL6+/CD10+ Mantle Cell Lymphoma: Meta-Analysis of Individual Patients and Systematic Review.International journal of molecular sciences · 2023Pooled it
- Trial
- Trial
- Trial
- Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.British journal of haematology · 2016Trial
- The utility of mRNA analysis in defining SOX11 expression levels in mantle cell lymphoma and reactive lymph nodes.Haematologica · 2015Trial
- Cutaneous Involvement by Blastoid Mantle Cell Lymphoma Presenting as Cervical Abscess: A Rare Extranodal Diagnostic Challenge.Journal of cutaneous pathology · 2026Article
- Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma.Nature communications · 2025Article
- Correlation between TP53 mutational status and digital quantification of p53 immunohistochemistry in mantle cell lymphoma.Virchows Archiv : an international journal of pathology · 2025Article
- Review
- Ironomycin induces mantle cell lymphoma cell death by targeting iron metabolism addiction.Theranostics · 2025Article
- Your chemo is no good here: management of high-risk MCL.Hematology. American Society of Hematology. Education Program · 2024Review
- Article
- Clinical and pathological characteristics of blastoid mantle cell lymphoma: a single institution experience.F1000Research · 2024Article
- Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.British journal of haematology · 2024Article
- Cell-free DNA in large B-cell lymphoma: MRD and beyond.Seminars in hematology · 2023Article
- Prognostic value and computer image analysis of p53 in mantle cell lymphoma.Annals of hematology · 2022Article
- Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma.Cancer reports (Hoboken, N.J.) · 2022Article
- Hematopoietic cell transplantation for mantle cell lymphoma.International journal of hematology · 2022Review
- Prognostic Value of Heterogeneity Index Derived from BaselineFrontiers in oncology · 2022Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) was created to enable stratification of the clinical diverse MCL patients into three risk groups. So far, use of the MIPI in clinical routine has been limited, as it has been shown that it inadequately separates low and intermediate risk group patients. To improve outcome and minimize treatment-related morbidity, additional parameters need to be evaluated to enable risk-adapted treatment selection. We have investigated the individual prognostic role of the MIPI and molecular markers including SOX11, TP53 (p53), MKI67 (Ki-67) and CCND1 (cyclin D1). Furthermore, we explored the possibility of creating an improved prognostic tool by combining the MIPI with information on molecular markers. SOX11 was shown to significantly add prognostic information to the MIPI, but in multivariate analysis TP53 was the only significant independent molecular marker. Based on these findings, we propose that TP53 and SOX11 should routinely be assessed and that a combined TP53/MIPI score may be used to guide treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.